Effect of ganaxolone on flurothyl seizures in developing rats

被引:36
作者
Liptáková, S
Velísek, L
Velísková, J
Moshé, SL
机构
[1] Dept Neurol, Bronx, NY 10461 USA
[2] Dept Neurosci, Bronx, NY 10461 USA
[3] Dept Pediat, Bronx, NY 10461 USA
[4] Montefiore Einstein Epilepsy Management Ctr, Bronx, NY 10461 USA
[5] Albert Einstein Coll Med, Bronx, NY 10467 USA
关键词
ganaxolone; seizures; rats; development; flurothyl;
D O I
10.1111/j.1528-1157.2000.tb00244.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose: To determine the effects of a newly synthesized epalon, ganaxolone (GNX), on primarily generalized seizures in rats of various ages during development. Epalons are classified as neuroactive steroids that interact at unique site of the GABA, receptor-Cl- channel complex in the central nervous system. Methods: Sprague-Dawley male rats were used at 9, 15, 30, and 60 postnatal days (PN). GNX dissolved in 2-hydroxypropyl-beta-cyclodextrine was administered intraperitoneally in different doses at various time points before flurothyl testing. The incidence and threshold of clonic and tonic-clonic flurothyl seizures were evaluated. Behavioral changes were also assessed. Results: In all age groups, the effects of GNX were dose dependent and more prominent 10 min after its administration. In PN 60 and PN 30 rats, GNX had dose-dependent anticonvulsant effects; tonic-clonic seizures were more sensitive to GNX treatment than clonic seizures. In PN 15 and PN 9 rats, GNX demonstrated dose- and time-dependent anticonvulsant effects against both types of flurothyl-induced seizures. GNX was more effective in PN 15 rats than in other age groups, but at doses that altered motor behavior. Conclusions: GNX has anticonvulsant effects against flurothyl-induced seizures in all age groups tested. Its effects are more prominent in the two younger age groups, especially in PN 15 rats, but are associated with motor side effects.
引用
收藏
页码:788 / 793
页数:6
相关论文
共 25 条
[1]  
Baulieu E. E., 1981, Steroid Hormone Regulation of the Brain, P3
[2]  
Beekman M, 1998, J PHARMACOL EXP THER, V284, P868
[3]   ANTICONVULSANT PROFILE OF THE PROGESTERONE METABOLITE 5-ALPHA-PREGNAN-3-ALPHA-OL-20-ONE [J].
BELELLI, D ;
BOLGER, MB ;
GEE, KW .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 166 (02) :325-329
[4]  
Carter RB, 1997, J PHARMACOL EXP THER, V280, P1284
[5]  
CRAIG CR, 1966, J PHARMACOL EXP THER, V153, P337
[6]  
Gasior M, 1997, J PHARMACOL EXP THER, V282, P543
[7]  
GEE KW, 1995, CRIT REV NEUROBIOL, V9, P207
[9]  
GOTTLIEB A, 1977, BIOL NEONATE, V32, P166
[10]   MODULATION OF THE GABA RECEPTOR COMPLEX BY A STEROID ANESTHETIC [J].
HARRISON, NL ;
SIMMONDS, MA .
BRAIN RESEARCH, 1984, 323 (02) :287-292